VCG
VIVO

Vantage Consulting Group’s Meridian Bioscience Inc VIVO Stock Holding History

Vantage Consulting Group’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,010
Closed -$19K – 1743
2020
Q4 		$19K Buy
+1,010
New +$18.9K ﹤0.01% 906

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vantage Consulting Group's VIVO Position: Q1 2021 in Review

Vantage Consulting Group sold out of Meridian Bioscience Inc (VIVO) in Q1 2021, closing a stake of 1,010 shares — an estimated $19K sold.

Vantage Consulting Group first reported a position in VIVO in Q4 2020 and held it in 1 quarter. The position peaked at $19K in Q4 2020. 215 funds tracked by Wall St. Rank hold VIVO as of Q1 2021.

  • Vantage Consulting Group reported no remaining Meridian Bioscience Inc position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 1,010 Meridian Bioscience Inc shares in Q1 2021, an estimated $19K.
  • Vantage Consulting Group first reported a position in Meridian Bioscience Inc in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Meridian Bioscience Inc position peaked at $19K in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.